BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 17547497)

  • 1. Combating the growing problem of methicillin-resistant Staphylococcus aureus: do the newer antibiotics represent a better alternative to vancomycin?
    Chambers HF; Hegde SS
    Expert Rev Anti Infect Ther; 2007 Jun; 5(3):333-5. PubMed ID: 17547497
    [No Abstract]   [Full Text] [Related]  

  • 2. Susceptibility to daptomycin, quinupristin-dalfopristin and linezolid and some other antibiotics in clinical isolates of methicillin resistant and methicillin sensitive S.aureus from the Oslo area.
    Jørgen B; Merckoll P; Melby KK
    Scand J Infect Dis; 2007; 39(11-12):1059-62. PubMed ID: 17852934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimizing therapy for MRSA pneumonia.
    Skrupky LP; Micek ST; Kollef MH
    Semin Respir Crit Care Med; 2007 Dec; 28(6):615-23. PubMed ID: 18095225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative activities of daptomycin, linezolid, and tigecycline against catheter-related methicillin-resistant Staphylococcus bacteremic isolates embedded in biofilm.
    Raad I; Hanna H; Jiang Y; Dvorak T; Reitzel R; Chaiban G; Sherertz R; Hachem R
    Antimicrob Agents Chemother; 2007 May; 51(5):1656-60. PubMed ID: 17353249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative activity of telavancin and other antimicrobial agents against methicillin-resistant Staphylococcus aureus isolates collected from 1991 to 2006.
    Shams W; Walker ES; Levy F; Reynolds SA; Peterson SM; Sarubbi FA
    Chemotherapy; 2010; 56(5):411-6. PubMed ID: 20948212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimizing therapy for methicillin-resistant Staphylococcus aureus bacteremia.
    Cosgrove SE; Fowler VG
    Semin Respir Crit Care Med; 2007 Dec; 28(6):624-31. PubMed ID: 18095226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Susceptibility of methicillin-resistant Staphylococcus aureus to vancomycin, teicoplanin, linezolid, pristinamycin and other antibiotics.
    Samra Z; Ofer O; Shmuely H
    Isr Med Assoc J; 2005 Mar; 7(3):148-50. PubMed ID: 15792257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Telavancin for the treatment of methicillin-resistant Staphylococcus aureus osteomyelitis.
    Twilla JD; Gelfand MS; Cleveland KO; Usery JB
    J Antimicrob Chemother; 2011 Nov; 66(11):2675-7. PubMed ID: 21831987
    [No Abstract]   [Full Text] [Related]  

  • 9. Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study.
    Florescu I; Beuran M; Dimov R; Razbadauskas A; Bochan M; Fichev G; Dukart G; Babinchak T; Cooper CA; Ellis-Grosse EJ; Dartois N; Gandjini H;
    J Antimicrob Chemother; 2008 Sep; 62 Suppl 1():i17-28. PubMed ID: 18684703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative bactericidal activities of daptomycin, glycopeptides, linezolid and tigecycline against blood isolates of Gram-positive bacteria in Taiwan.
    Huang YT; Liao CH; Teng LJ; Hsueh PR
    Clin Microbiol Infect; 2008 Feb; 14(2):124-9. PubMed ID: 18076671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diminished vancomycin and daptomycin susceptibility during prolonged bacteremia with methicillin-resistant Staphylococcus aureus.
    Bennett JW; Murray CK; Holmes RL; Patterson JE; Jorgensen JH
    Diagn Microbiol Infect Dis; 2008 Apr; 60(4):437-40. PubMed ID: 18096352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05.
    Steinkraus G; White R; Friedrich L
    J Antimicrob Chemother; 2007 Oct; 60(4):788-94. PubMed ID: 17623693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monte Carlo simulation analysis of ceftobiprole, dalbavancin, daptomycin, tigecycline, linezolid and vancomycin pharmacodynamics against intensive care unit-isolated methicillin-resistant Staphylococcus aureus.
    Salem AH; Zhanel GG; Ibrahim SA; Noreddin AM
    Clin Exp Pharmacol Physiol; 2014 Jun; 41(6):437-43. PubMed ID: 24341387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparative in-vitro evaluation of resistance selection after exposure to teicoplanin, vancomycin, linezolid and quinupristin-dalfopristin in Staphylococcus aureus and Enterococcus spp.
    Drago L; Nicola L; De Vecchi E
    Clin Microbiol Infect; 2008 Jun; 14(6):608-11. PubMed ID: 18397336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bacteremia and infective endocarditis caused by a non-daptomycin-susceptible, vancomycin-intermediate, and methicillin-resistant Staphylococcus aureus strain in Taiwan.
    Huang YT; Hsiao CH; Liao CH; Lee CW; Hsueh PR
    J Clin Microbiol; 2008 Mar; 46(3):1132-6. PubMed ID: 18199793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activity of daptomycin against clinical isolates with reduced susceptibilities to linezolid and quinupristin/dalfopristin.
    Anastasiou DM; Thorne GM; Luperchio SA; Alder JD
    Int J Antimicrob Agents; 2006 Nov; 28(5):385-8. PubMed ID: 17046205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activities of tigecycline, daptomycin, linezolid and quinupristin/dalfopristin against glycopeptide-resistant Enterococcus faecium.
    Abb J
    Int J Antimicrob Agents; 2007 Mar; 29(3):358-60. PubMed ID: 17229553
    [No Abstract]   [Full Text] [Related]  

  • 18. In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model.
    Jacqueline C; Caillon J; Le Mabecque V; Miègeville AF; Hamel A; Bugnon D; Ge JY; Potel G
    Antimicrob Agents Chemother; 2007 Sep; 51(9):3397-400. PubMed ID: 17591849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents.
    Bogdanovich T; Clark C; Kosowska-Shick K; Dewasse B; McGhee P; Appelbaum PC
    Antimicrob Agents Chemother; 2007 Nov; 51(11):4191-5. PubMed ID: 17875997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of reduced vancomycin susceptibility in methicillin-susceptible Staphylococcus aureus.
    Pillai SK; Wennersten C; Venkataraman L; Eliopoulos GM; Moellering RC; Karchmer AW
    Clin Infect Dis; 2009 Oct; 49(8):1169-74. PubMed ID: 19769538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.